Form 4: Myriad Genetics Director Colleen F. Reitan Reports Acquisition of Common Stock

Director Colleen F. Reitan reported acquiring 15,695 shares of Myriad Genetics Inc. common stock and disposing of shares, resulting in a total beneficial ownership of 88,545 shares.

Summary

• On June 6, 2024, Colleen F. Reitan, a director of Myriad Genetics Inc., reported a transaction involving the company's common stock.
• Reitan acquired 15,695 shares of common stock at $0.
• Following the transaction, Reitan's beneficial ownership of Myriad Genetics Inc. common stock totaled 88,545 shares.
• The acquisition was related to restricted stock units granted under the company's 2017 Employee, Director and Consultant Equity Incentive Plan.
• These restricted stock units vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing and does not inherently convey positive or negative sentiment. It simply reports a transaction.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates